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ABSTRACT
According to World Health Organization (WHO), cancer is the second leading cause of
death worldwide, with 9.6 million deaths in 20181. In the United States, an estimated 434,982
people were living with cancer during 2017 2. Leukemia is the most common blood cancer in
children from birth to 14 years old 3 . In particular, Hispanic children in the United States
experience a higher incidence rate of leukemia 4 . Therefore, the discovery of novel cancer
therapies is necessary to help those affected survive the disease. A new compound, LMDF5-7
was investigated and found to have anticancer properties that can help to treat cancer. To
determine how this compound kills cancer cells, we evaluated its potential to activate cell death
pathways by searching for mitochondria depolarization, reactive oxygen species (ROS)
production, caspase-3 activation, and cell cycle proliferation. In this work, we evaluated the
cytotoxic effects of LMDF5-7 in various cancer cell lines and demonstrated potent cytotoxicity
against cancer cells, specifically leukemia cells. LMDF5-7 is a novel compound that targets
cancer cells and is less sensitive to non-cancerous cells. This compound induces cell death,
causes accumulation of ROS, and leads to the loss of mitochondrial membrane integrity.
Additionally, this compound disrupted cell cycle progression that caused DNA fragmentation
and induced apoptosis in a T-lymphoblast leukemia cell line.
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INTRODUCTION
One out of six deaths is due to cancer worldwide, making it the second leading cause of death in
the world1. Cancer is the rapid production of abnormal cells that grow beyond their usual limits.
Cancer cells remove normal cell division restrictions, create uncontrollable growth and abnormal
functions. There are more than 277 different types of cancer, and there are many different stages
that are indicated by gene mutations5. Cancer cells can invade adjacent parts of the body and
spread to other organs, known as metastasis 6. The malfunctions that cause the uncontrollable
growth can develop into a lump, mass, or tumor, but some cancers involve the blood or bloodforming organs where they do not form tumors.7

Several risk factors may increase your chances of getting cancer. The chances of being
diagnosed with cancer depend on age, family history, lifestyle, health conditions, and habits such
as smoking and drinking8. Also, socioeconomic status can have an impact on treatment and
survival rates. Wealthy countries have access to information about the disease, a better health
system, quality treatment, and survivorship care, leading to improved survival rates of some
cancer types due to early detection. However, the most affected and least prepared are lowincome and middle-income countries that do not have access to quality diagnosis and treatment. 9
In the United States, there were an estimated 1,806,590 cancer cases and 606,520 deaths in
202010. Cancer will affect a larger group of the United States population by 2021. It is expected
to reach almost 1.9 million new cases, and approximately 608,570 Americans are expected to die
of cancer, especially since COVID-19 increases the risk 11.

It is estimated that every 3 minutes, one person in the US is diagnosed with blood-related
cancer12. Blood cancer is known as leukemia, and it involves the bone marrow and the lymphatic
1

system. Several types of leukemia exist. The most common and fast-growing ones are Acute
Lymphocytic Leukemia (ALL) and Acute Myeloid Leukemia (AML)13. Leukemia develops
when the DNA in blood cells, known as leukocytes, change and mutate, leading to
uncontrollable proliferation14. Normally, white blood cells are only about 1% of your blood and
responsible for protecting us against illness and disease 15. The white blood cells are potent
infection fighters in our bodies, and they grow and divide as needed. The bone marrow of people
with leukemia produces an excessive amount of abnormal white blood cells, surpassing red
blood cells and cause cancer 16.

Chemotherapy, surgery, and radiotherapy are the most common types of cancer treatments
available nowadays17. Several problems exist with the proper selection of cancer treatments.
These include unavailability of effective biomarkers, metastasis, among others, but especially
drug resistance18. Resistant cancer cells develop certain unique mechanisms by which they can
escape harmful agents.19.The variety of drugs that exist are for personalized medicine that
depends on your cancer type, stage, chemical composition, or other. These can be used alone or
in combination20. Drug development and the design of treatments will benefit from
incorporating several hallmarks and multiple biochemical pathways 21. Cancer cells have
different hallmarks that make them unique. Effective anticancer drugs focus on targeting several
hallmarks to induce cell death21.
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Significance
It is important to implement research in cancer since this past year, and the world
experienced a pandemic due to COVD-19, which mainly attacks the immune system. A study
from the United Kingdom explained that patients with blood cancer were at a greater risk of
experiencing a severe case of COVID-19 compared to patients with other cancer types and had
an even higher likelihood of dying from the virus if on chemotherapy 22.
Leukemia is the most common cancer in children and teens, accounting for almost one
out of three incidences23. The survival rate of leukemia cancer is about 69 of 100 persons who
typically live at least five years after diagnosis depending on the type 24. The investigation of
new treatments and drug discovery is necessary to increase survival rates and give patients other
options in case of resistance. Cancer can persist and eventually re-grow after time, especially in
late-stage tumors25. Dr. Mirna Rivera found a novel compound at the University of Puerto Rico
at Humacao, which can target several cancers. The collaborator has not released many details of
the compound, named LMDF5-7, since they are still working on published data, but anticancer
properties have been observed. My research will contribute to this data as I evaluate the
biochemical effects of this compound on cancer cells.

Specific Aims. My research focuses on testing the novel compound LMDF5-7 against cancer
cells to investigate the cytotoxic effects. Dr. Aguilera’s lab focuses on in vitro screening of
several possible cancer drugs. This thesis aims to understand how the compound affects cancer
and non-cancer cells while looking for a piece of better knowledge on the molecular and cellular
level of cancer research. Cancer has several hallmarks, some therapies focus on a single target,
but it may be more feasible to conduct multiple assays to check the efficiency of the compound.
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The main goal is to identify the potential of this compound to be an anticancer drug and its
molecular mechanism of action.
Specific Aim1. Evaluation of the cytotoxic effects of LMDF5-7 in various cancer cell lines.
Investigate cytotoxic and selective effects on several cancer cells and non-cancer cells by the
DNS assay.
Specific Aim 2. Investigation of the potential of LMDF5-7 to induce apoptosis in a Leukemia
cell line. For this aim, we determine that the mode of action of LMDF5-7 is programmed cell
death. Analyze the health of the mitochondrial membrane by the examination of depolarization
of such. Additionally, we search for reactive oxygen species which can cause excess oxidative
stress, cause damage to the mitochondria and induce cell death. Observe the activation of the
caspase-3 enzyme due to its functional role in the apoptosis cascade. Finally, we examine how
the compound can affect the progression of the cell cycle by a flow cytometer.

4

MATERIALS AND METHODS
Cell lines. All the cell clines are incubated at 37°C and humidified with a 5% CO 2 atmosphere.
Lymphoma/leukemia (CEM, NALM-6, and RAMOS) cell lines were cultured in RPMI-1640
medium (Hyclone, Logan UT) supplemented with 100 U/mL of penicillin, 100 μg/ mL of
streptomycin (Lonza, Walkersville, MD), and 10% fetal bovine serum (FBS; Hyclone). HL60 cells
were grown in 20% of FBS and the same medium as the other leukemia cell lines mentioned
before. The breast cancer (MDA-MB-231), pancreatic cancer (PANC-1), and fibroblast (HS-27)
cell lines were grown in DMEM medium (Hyclone) supplemented with 10% FBS (Hyclone), 100
U/mL of penicillin, and 100 μg/mL of streptomycin (Lonza). Finally, MCF-10A cells were grown
in DMEM F/12 media with 10% FBS, 100 U/mL of penicillin, and 100 μg/mL of streptomycin.
Furthermore, 20 ng/mL of epidermal growth factor (EGF), 0.5 μg/mL of hydrocortisone, and 10
μg/mL of insulin were added to the MCF-10A cell line.

Differential nuclear staining assay (DNS). The purpose of this assay is to examine the potential
cytotoxicity of LMDF5-7. The DNS assay identifies live and dead cells using two different nucleic
acid fluorescent dyes: Hoechst, a blue dye (Invitrogen, Eugene, OR, USA), and Propidium Iodide
a red dye (PI; MP Biomedicals, Solon, OH, USA)26. Hoechst stains the nuclei of healthy and dead
cells (total cells), and PI only stains the dead cells. Cells were seeded in 96-well microplates at a
density of 10,000 cells per well in 100 μL of media and incubated overnight. Then, LMDF5-7 was
added at different concentrations. The controls used for the experiment were the following: a
vehicle (1% DMSO), a positive control (H202), and untreated cells. Two different incubation
times, 48 and 72 h were used. Two hours before imaging, the mixture of fluorescent dyes (1 μg/mL
final concentration) was added to each well and incubated before the analysis image.

5

For the

captured images from the plate, the IN-Cell Analyzer 2000 system was used (GE Healthcare,
Pittsburg PA, USA). Then the IN Cell Analyzer Workstation 3.2 software (GE Healthcare) was
used to segment and analyze both living and dead cells. Before preparing the experimental plate,
the cell viability (at least 95% viable) was determined using PI staining and the Gallios flow
cytometer (Beckman Coulter, Miami, FL).

Cytotoxic concentration 50% (CC50) and selective cytotoxicity index (SCI) values. The IN Cell
Analyzer Workstation 3.2 software that was used for the DNS assay analysis gave the numbers for
each cell subpopulation and from each individual well. Then, the CC 50 and SCI could be calculated.
The CC50 is the concentration needed to kill 50% of the cell population by the compound 27.The
percentage of dead cells obtained from the vehicle control (DMSO) was subtracted from each
individual experimental point to eliminate the background of dead cells. Next, a linear
interpolation equation was used to determine the CC 50 value. A selective cytotoxicity index (SCI)
determines the selective toxicity of a drug in cancer cells compared to a non-cancerous cell line
(Hs27 and MCF-10A). For the calculation, the CC 50 for the non-cancerous control was divided by
the CC50 of the cancer cells.

Cell cycle analysis by flow cytometer. Two 24-well plates with CEM cells at a concentration of
100,000 cells in 1 mL of culture media per well were used. Cells were treated with 0.06 μM
(CC10) ,0.13 μM (CC20) and 0.20 μM (CC30) of LMDF5-7 for 48 and 72 h. The controls included
for this experiment were DMSO, untreated, and hydrogen peroxide as a positive control. Then,
cells were collected in flow cytometry tubes and centrifuged at 262g for 5 min. Then, the
supernatant was discarded and gently resuspended in 100 μL of culture media. Before using the

6

flow cytometer, we added 200 μL of nuclear isolation medium (NIM)-DAPI solution (NPE
Systems, Inc. Pembroke Pines, FL, USA)28. Then we read the samples in the flow cytometer
(10,000 events) and looked for the different stages of the cell cycle. The NIM-DAPI reagent can
quantify DNA content at different stages using an FL-9 detector that detects the fluorescent
signal and the 405-nm laser (Gallios).

Reactive oxygen species detection assay. We conducted via carboxy-H2 DCFDA (6-carboxy2’,7’-dichlorodihydrofluorescein diacetate) indicator of oxidative using flow cytometry 29.CEM
cells were seeded in 24-well plates at a concentration of 100,000 cells per well, 1 ml of media, and
incubated overnight at F°C. Then, we added controls used before and LMDF5-7 compound and
incubated it for 18h. Each well was collected in flow cytometer tubes, centrifuged for 5 min at
262g, and decanted the supernatant to keep the pellets. We resuspended in a mixture of pre-warmed
PBS and the carboxy-H2 DCFDA with a final concentration of 10 μM (loading buffer). After that,
the flow cytometer tubes with the cells were placed back into the incubator for 1 h at 37°C. When
the incubation is over, remove the loading buffer, carefully spin down the tube, and add 500 μL of
PBS. As a final step, we incubated for 30 min at 37°C. Immediately we read with the Gallios flow
cytometer (Beckman Coulter), acquiring 10,000 cells per sample, and analyzed via Kaluza
software (Beckman Coulter).

Analysis of mitochondrial membrane potential via JC-1 assay. The MitoProbe JC-1 assay kit
(Molecular Probes, M34152) and flow cytometry were used to analyze the mitochondrial
depolarization28. We plated CEM cells in a 24-well with 100,000 cells and 1 mL of cell culture
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media per well. The CEM cells were treated with LMDF5-7 and the same controls mentioned
before in triplicate for 5 h. Then, we collected cells in flow cytometer tubes and centrifuged them
at 262g for 5 min. Next, we decanted the supernatant and resuspended with 500 μL media
containing 5 μL (2 μM final concentration) of JC-1 reagent (5’,6,6’-tetrachloro-1,1 ‘,3,3 ‘tetraethylbenzimidazolylcar-bocyanine iodide) and incubated at 37 °C, 5% CO 2 for 45 min. Cells
were washed once with pre-warmed PBS after incubation. Immediately analysis at the flow
cytometry by the Kaluza software (Beckman Coulter).

Analysis of apoptosis/necrosis by Annexin V-FITC/PI assay. These experiments are used to
explore whether LMDF5-7 induces apoptosis or necrosis as the mechanism of cell death. The
Annexin V-FITC Kit was utilized (Beckman Coulter, Miami, FL, USA) with CEM cells seeded in
24-well plates at a concentration of 100,000 cells per well with 1 mL of culture media and
incubated overnight at 37°C. Treatments were applied to cells in triplicate and incubated for an
additional 24 h. After the incubation, cells were collected in flow cytometry tubes and centrifuged
for 5 min at 262g. Each pellet was resuspended in 103.5 μL of the following mixture: 100 μL of
the 1× binding buffer, 1 μL Annexin V-FITC, and 2.5 μL of propidium iodide 28.To facilitate the
exposure of the fluorophores, we resuspended them again and kept them on ice for 20 min in the
dark. Afterward, we added 300 μL of ice-cold binding buffer to each tube and analyzed via flow
cytometry (Cytomics FC 500, Beckman Coulter) and the Kaluza software (Beckman Coulter).

Caspase-3 assay. For this assay, HL-60 cells were plated in 24-well plates (100,000 cells). The
assay consists of a fluorogenic substrate which is cleaved by an active caspase-3 using NucView
488 caspase-3 substrate assay kit (Biotium, Hayward, CA), releasing a product that after binding
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to the DNA emits a bright green fluorescence signal. The cells emitting a green signal are positive
to caspase-3 active, meaning apoptotic cell; incubate at 6 h with controls and compound. After the
incubation, cells were placed in flow cytometry tubes and centrifuged at 262g for 5 min. Cell
pellets were gently disrupted by adding 200 μL of PBS containing 5 μL of NucView 488 Caspase3 substrate (5 μM final concentration) and incubated 30 min at room temperature in the dark. Then
we added 300 μL of PBS and analyzed it by flow cytometry. Data was of 10,000 events and
analyzed by using Kaluza Flow Cytometry Software (Beckman Coulter).

Statistical analysis. Each experimental point signifies at least three independent measurements.
All findings are shown as the multiple measurements with their corresponding standard deviations
to denote our experimental variability. The statistical significance of the differences between two
experimental samples was performed using a two-tailed Student's t-test, and a P-value equal to or
less than 0.05 was considered significant.
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RESULTS
Compound LMDF5-7 is cytotoxic and selective against cancer cells: The Differential
Nuclear Staining assay can determine CC50, which is the value concentration of the compound
that causes 50% of cell death as compared to solvent-treated and how selective it is against
cancer cells30. The Selective Cytotoxicity Index (SCI) determines how selective the toxicity of
a compound is in cancer cells compared to non-cancerous cell lines. The equation for SCl=
CC50 of the non-cancerous cell over CC50 of cancer cell and the values greater than 1 were
deemed selective.
The compound was tested in 8 different cell lines, and the effects of each one are in Table 1.
The best results obtained were in the CEM cell line with a CC 50 of 0.33uM, and the secondbest result was another leukemia cell line, HL-60, with a CC 50 of 0.70 uM. The Selective
Cytotoxic Index indicates the compound is highly selective against leukemia cell lines for both
cell lines28 . To calculate the Selective Cytotoxic Index (SCI), the CC 50 of non-cancer cells is
needed, and the two cell lines tested were Hs27, a fibroblast, and MDF-10A, a Fibrocystic
Diseases. However, the only one used for the calculation was Hs27. We could not detect a CC 50
lower than 100 uM with MCF-10A, and we could not go higher due to issues with dissolving
the compound at a higher concentration.
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Table 1: CC50 and SCI values of LMDF5-7-treated cancerous and non-cancerous cells.
Note: On the top of the third column (left to right) should read CC 50 [µM]

DNS is an assay applicable to high content primary screens for identifying cytotoxic activity,
especially cancer drug screening to determine CC 50 and SCI. After analyzing the results, we
detected that the LMDF5-7 compound was more cytotoxic towards T-cell leukemia cell lines.
CEM is the cell line selected to continue with the other assays because it is highly selective and
has a lower CC50 than other cell lines.

Cell cycle in CEM cell line at 48 and 72 hours by flow cytometer. The quantitative
fluorescent staining by NIM-DAPI can quantify DNA content at different stages. Flow
cytometric (FCM) is a rapid analysis of cellular DNA and evaluates DNA contents for obtaining
cell-cycle frequency distributions31. The assay was done at different time-lapses: 48 and 72 hours
since the cell cycle needs more time to complete each stage. This assay aims to look for changes
or alterations in the cell cycle and look for DNA fragmentation, one of the apoptosis hallmarks.
For the cell cycle assay, the concentrations were CC10, CC20, and CC30 because, at lower
concentrations, the cells are allowed to complete the cell cycle and not be as aggressive as CC 50.
11

Figure 1 shows the cell cycle at 48 hours, demonstrating that Sub-G0/G1(A) has DNA
fragmentation compared to the H2O2 (our positive control). The percentages of the cell cycle
phases look as DMSO or non-treated, meaning that the LMDF5-7 compound is not altering the
cell cycle progression. However, the sub-G0/G1 subpopulation has significantly increased,
suggesting that the LMDF5-7 compound can induce DNA fragmentation.

Figure 1. Analysis of CEM cell line in cell cycle profile by flow cytometry at 48 hours.
Results show DNA fragmentation at Sub-G0/G1(A).
Note: It should read CC10, CC20, and CC30. It is highly recommended to use Arial font in all
the figures, numbers, and letters. Please, be consistent in all the Figures.
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Results in Figure 2 at 72 hours, the CEM cells have more time to reproduce and complete a
cell cycle. The DNA fragmentation is higher in Sub-G0/G1(A), and similarly to the 48 h
experiment, a non-discernible arrest was detected. After, the cell cycle looks disrupted, and
the compound has a similar effect as our positive control H 2O2.

Figure 2. The cell cycle profile of CEM cell line after 72 hours of LMDF5-7 compound
exposure. Demonstrate DNA fragmentation in Sub G0/G1(A).
Note: It should read CC10, CC20, and CC30.

Apoptotic cells can be identified since the low molecular weight and content frequency
histograms as cells with fractional sub-G0/G132. Figure 1 shows a DNA fragmentation, but in
comparison with Figure 2, the DNA fragmentation is more compatible with our positive control
H2O2 and shows a change in the other phases. Both times demonstrate that LMDF5-7 causes
13

DNA fragmentation and distrust the continues of the cell cycle. The other phases, S and G2/M,
in Figure 1 and Figure 2 show an unfavorable cell cycle progression.

Reactive Oxygen Stress (ROS) induced by LMDF5-7 in a Leukemia cell line. Reactive
oxygen species have different signaling functions and are free/non-radicals, ions, or molecules
with a single unpaired electron in their outermost shell of electrons 33. Oxygen radicals are
potent DNA-damaging agents that cause DNA strand breaks if an excess of ROS exists,
induce cell death, and not let the proliferation continue34.
For this assay, the probe that LMDF5-7 causes oxidative stress is a positive control. Hydrogen
peroxide (H2O2) has been recognized as destructive molecules because they induce
endogenous ROS35. Typically, if ROS is at low cellular concentrations, they allow
proliferation and help have proper function of intracellular signaling and regulation 36.
Figure 3 indicates accumulation and disturbs cellular homeostasis by ROS exposure. Excess
of oxidative stress leading to cell death, known as apoptosis, tested in both compound’s
concentrations. LMDF5-7 demonstrates the hallmark oxidative stress and acting similarly to
H2O2. DMSO and Untreated cells as negative control and p-value≤0.05 (*) was deemed
significant.
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Figure 3. Accumulation to initiate cell death by Reactive Oxygen Stress (ROS) in CEM cell
line for 18 hours with LMDF5-7 exposure at a concentration of 1 µM.
Note: It should read CC50, and CC100.

LMDF5-7 compound induces apoptosis. The Annexin V-FITC and propidium iodide (PI) (PI)
kit is helpful to investigate whether the mechanism of cell death induced by LMDF5-7
compound is via apoptosis or necrosis. Cells experiencing apoptosis externalize the
phosphatidylserine (PS) to the outer leaflet, which is typically confined to the plasma
membrane's inner leaflet. Cells were monitored via flow cytometry after dual staining Annexin
V-FITC and PI. The calcium-dependent binding of Annexin V can detect exposed PS, but in
healthy cells, the PS is not detected since it is in the inner leaflet 37. In necrotic cells, PI can
penetrate the damaged plasma membrane and complex with nucleic acids. The fluorescence of
Annexin V-FITC-PS complexes on only apoptotic cells was detected by flow cytometry after 24
hours of exposure.

15

Figure 4. Phosphatidylserine externalization to identify apoptotic cells. Percentage of
apoptotic cells (stained with Annexin V-FITC) and propidium iodide (PI) after 24-hour
incubation with LMDF5-7 at a concentration of 1 µM
Note: The letters and numbers size font of the labels in the graph is tiny and fuzzy.

The results in Figure 4 demonstrated programmed death was the mode of action for the
compound LMDF5-7. The results do not detect necrosis. When comparing our compound
with the other controls DMSO and untreated, a normal continuation of growth without cell
death, we observed that LMDF5-7 caused apoptosis to the CEM cell line at the concentration
CC50 and CC100 a P-value≤0.0001 (*).

Analysis of mitochondrial membrane potential: The mitochondria use oxidizable substrates
to produce an electrochemical proton gradient across the membrane used to produce energy
(ATP)38. Also, it transports ions and proteins, which are necessary for healthy mitochondrial
function. The mitochondrial membrane potential, known with the symbol ΔΨm, maintains
homeostasis by selective elimination of dysfunctional mitochondria 39. If depolarization or
16

decreases of mitochondria membrane potential is present, meaning a dysfunctional or
unhealthy mitochondrion, cell death can occur. Increased intrinsic ROS stress causes
malfunction of the mitochondrial to let the depolarization happen and alters cellular function
to induce apoptosis40.
For the experiment know as JC-1, we look to see if the LMDF5-7 compound causes a
depolarization as H2O2 to induce unhealthy mitochondria.
Figure 5 showed the compound increased dose-dependent mitochondrial depolarization that
was statistically significant compared to the solvent (P< 0.05) and untreated controls. The CC 100
results in a decrease of mitochondria membrane potential after 6 hours of incubation in the CEM
cell line. As the ROS experiment demonstrated oxidative stress in the CEM cell line exposed
to the LMDF5-7 compound, we believe there is a malfunction in the mitochondria. These
indicate apoptosis was detected as the mode of action of LMDF5-7 and causes loss of membrane
integrity.

17

Figure 5. Analysis of cells with depolarized mitochondria after 6-hour treatment with 1 µM
LMDF5-7 observed by JC-1 dye which emits a green fluorescence signal.
Note: It should read CC50, CC100, and H2O2.

LMDF5-7 Compound Caused Activation of Caspase-3 in Leukemia Cell line. Caspases
family is known as mediators of programmed cell death (apoptosis), especially caspase-3, that
activate death proteases and catalyze a specific cleavage of proteins 41. Executioner caspase-3
is responsible for inhibiting electron transport through electrons and lowering the
mitochondrial membrane potential ΔΨm to decrease ROS production due to apoptosis 42.
Therefore the detection of caspase-3 has a key role in detecting apoptosis as a mode of action
created by LMDF5-7.
The experiment consists of a caspase-3 peptide cleaving the substrate DEVD, releasing the
high-affinity DNA dye, which migrates to the cell nucleus and stains DNA with fluorescence.
The caspase cleavage in the apoptotic cell and the dye released a fluorescent dye in the
nucleus can be detected by flow cytometry 43.
18

Figure 6. Activation caspase-3 was observed in HL 60 cells after treatment with 1 µM of the
LMDF5-7 compound for 8 hours.
Note: It should read CC50, and CC100.

In Figure 6, we observed caspase-3 activation after 8 hours of incubation with the CC 100 in
HL60 cells. Demonstrating apoptosis as the mode of action and caspase-3 is essential to the
compound's activity against the T-cell leukemia cell line.
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DISCUSSION
Cancer has several hallmarks. Nowadays, effective anticancer compounds need to focus on
several of these hallmarks to be more efficient. The LMDF5-7 compound has better results with
T-cell leukemia and demonstrates anticancer properties. Our goal was to analyze cytotoxicity
and if the compound induces the apoptosis pathway.
The first specific aim was to evaluate the cytotoxic effects of LMDF5-7 in various cancer cell
lines. The experiment differential nuclear staining (DNS) was able to detect the concentration
values of the compound required to reduce cell viability by 50% and detect the selectivity in
cancer cells compared to non-cancerous cell lines. In the early discovery process, we must
calculate the CC50 to evaluate the compound's suitability and performance 44. We demonstrated
leukemia, especially the CEM cell line, has better results after treatment with LMDF5-7. Then,
to continue with the cytotoxic effects, we examined the cell cycle and its major phases: G0/G1,
S, and G2/M, including Sub-G0/G1. Apoptotic cells often have fractional DNA content
represented on the histograms by the sub-G0/G145. Our Figures 1 and 2 demonstrate DNA
fragmentation in the Sub-G0/G1, meaning the compound is inducing cell death/damage. Also,
disruption continues in the other stages and especially in Figure 2, the G0-G1 phase. The G1
phase plays an important role in cancer since it is in charge of signaling, cell growth,
proliferation, stress management, and survival. It is also crucial in helping to define how cancer
works and shows promising results in cancer therapies 46. The last assay for the first specific aim
to evaluate cytotoxic effects, was reactive oxygen species. The excess of ROS production is
responsible for damages in DNA, proteins, and lipids and may have cell dysfunctions that result
in apoptosis29. The overproduction of oxidative stress causes mitochondrial membrane
depolarization, which initiates the activation of the intrinsic apoptotic pathway and impairing
20

protease activity47. The results show ROS overproduction in the CEM cell line. In summary, for
our first specific aim, compound LMDF5-7 is cytotoxic to T-cell leukemia cell line and
interferes with the proliferation, as demonstrated through the cell cycle and ROS.
The second specific aim was to investigate the potential of LMDF5-7 to induce apoptosis in a
leukemia cell line. We used the Annexin/PI staining strategy to confirm whether the LMDF5-7
compound was using apoptosis or necrosis as its mechanism to inflict cell death. Our results
demonstrated LMDF5-7 induces programmed death in the leukemia cell line. Next, was analyzed
the mitochondrial membrane potential by using the JC-1 reagent. We revealed that LMDF5-7 is
causing mitochondrial depolarization, indicating the activation of the intrinsic apoptotic pathway
preceding membrane damage48. Mitochondrial membrane potential is the redox transformations,
generators of ATP, metabolites for macromolecules, reactive oxygen species, and as an
intermediate form of energy storage49. The results obtained reveal that the compound causes
depolarization and decreases the mitochondrial membrane potential (ΔΨm). For cancer research,
an unhealthy mitochondrial is by depolarization that induces cell death 50. It is concluded that
apoptosis is cell-death programmed that is mediated by proteases called caspases and by proteins
of the Bcl2 associate with the mitochondrial outer membrane 51. The caspase-3 assay was done to
conclude if the compound induces apoptosis. Caspase-3 can have multiple effects critical for cell
death and implicating events such as cell shrinkage, blebbing, chromatin condensation, and
fragmentation52. In cancer, higher levels of activated caspase 3 in tumor tissues lead to increased
cell death53 . Our compound was positive for caspase-3 activation in the leukemia cell line and
indicated apoptosis. Moreover, during the cell cycle analysis, we have shown that LMDF5-7
induced DNA fragmentation, evidenced by an increment in the sub-G0/G1 subpopulation.

21

In summary, the novel compound LMDF5-7 induces cell death in cancer cells. The assays
performed were phosphatidylserine externalization, mitochondrial depolarization, caspase-3
activation, DNA fragmentation, and disrupted cell cycle progression to demonstrate the effects of
the LMDF5-7 compound.

CONCLUSION
Our data evidenced that LMDF5-7 is a novel compound that targets cancer cells, especially
leukemia. It is cytotoxic and selective against cancer cells, and non-cancerous cells are more
resistant to the LMDF5-7 compound. It interferes with the activity of the cell cycle and causes
DNA fragmentation. In addition, LMDF5-7 causes accumulation of ROS, indicating the
possibility of oxidative stress-induced cell death. Apoptosis was detected as the mode of action
of LMDF5-7. It damages the mitochondrial membrane integrity by depolarization and activates
Capsase-3 activation causing cell death/apoptosis.
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